Literature DB >> 2980242

Effects of relaxin on the microvasculature of mouse mammary gland.

G Bani1, T Bani Sacchi, M Bigazzi, S Bianchi.   

Abstract

The effects of RLX on the microvasculature of the mouse mammary gland are reported. RLX (pure porcine standard NIH-RXN-P1) at a dose of 3 GPU was administered subcutaneously to virgin adult mice ovariectomized 12 days before. The mammary glands were removed 18-20 h after RLX injection and their examination by light microscopy did not reveal any substantial growth-response to the hormone. Histology and morphometry indicated striking dilation of microvessels, especially capillaries, and electron microscopy revealed an increase in the micropinocytotic vesicles, thus suggesting enhanced transendothelial transport of substances. Such phenomena, which were independent of a release of granules by mast cells, may represent an important component of the mammotrophic action of RLX.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2980242

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN： 0213-3911            Impact factor:   2.303


  8 in total

1.  Relaxin inhibits histamine release from mast cells: involvement of nitric oxide production.

Authors:  E Masini; M G Di Bello; D Bani; M Bigazzi; T Bani Sacchi; P F Mannaioni
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

2.  Associations between serum relaxin 2, aneurysm formation/size and severity of atherosclerosis: a preliminary prospective analysis.

Authors:  Konstantinos Papoutsis; Alkistis Kapelouzou; Diamantis I Tsilimigras; Nikolaos Patelis; Georgios Kouvelos; Dimitrios Schizas; Ioannis Karavokyros; Sotirios Georgopoulos
Journal:  Acta Pharmacol Sin       Date:  2018-03-22       Impact factor: 6.150

Review 3.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

4.  Relaxin-induced increased coronary flow through stimulation of nitric oxide production.

Authors:  T Bani-Sacchi; M Bigazzi; D Bani; P F Mannaioni; E Masini
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

5.  Effects of relaxin on mast cells. In vitro and in vivo studies in rats and guinea pigs.

Authors:  E Masini; D Bani; M Bigazzi; P F Mannaioni; T Bani-Sacchi
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  Luteal and hypophyseal expression of the canine relaxin (RLN) system during pregnancy: Implications for luteotropic function.

Authors:  Marta Nowak; Alois Boos; Mariusz P Kowalewski
Journal:  PLoS One       Date:  2018-01-24       Impact factor: 3.240

Review 7.  Relaxin as a natural agent for vascular health.

Authors:  Daniele Bani
Journal:  Vasc Health Risk Manag       Date:  2008

Review 8.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.